DR-0202

N/A

Report date: 2026/04/14 20:00:15

First In Class

Base Information

Drug NameDR-0202

Drug Alias NameDR-0202

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionPhagocytes stimulantsMyeloid cell stimulantsAnti-Trop-2 +[4]

TargetsTumor-associated calcium signal transducer 2C-type lectin domain family 7 member A

Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursProstatic Neoplasms, Castration-Resistant +[13]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesDren Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesDren Bio Inc

Inactive CompaniesN/A

Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursProstatic Neoplasms, Castration-Resistant +[13]

Inactive IndicationsN/A

Other Information

ATC CodeN/A